^
    11ms
    Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=176, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    HS-10370
    almost2years
    Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=176, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    HS-10370